The C5a Receptor (C5aR) C5L2 Is a Modulator of C5aR-mediated Signal Transduction*

The complement anaphylatoxin C5a is a proinflammatory component of host defense that functions through two identified receptors, C5a receptor (C5aR) and C5L2. C5aR is a classical G protein-coupled receptor, whereas C5L2 is structurally homologous but deficient in G protein coupling. In human neutrophils, we show C5L2 is predominantly intracellular, whereas C5aR is expressed on the plasma membrane. Confocal analysis shows internalized C5aR following ligand binding is co-localized with both C5L2 and β-arrestin. Antibody blockade of C5L2 results in a dramatic increase in C5a-mediated chemotaxis and ERK1/2 phosphorylation but does not alter C5a-mediated calcium mobilization, supporting its role in modulation of the β-arrestin pathway. Association of C5L2 with β-arrestin is confirmed by cellular co-immunoprecipitation assays. C5L2 blockade also has no effect on ligand uptake or C5aR endocytosis in human polymorphonuclear leukocytes, distinguishing its role from that of a rapid recycling or scavenging receptor in this cell type. This is thus the first example of a naturally occurring seven-transmembrane segment receptor that is both obligately uncoupled from G proteins and a negative modulator of signal transduction through the β-arrestin pathway. Physiologically, these properties provide the possibility for additional fine-tuning of host defense.

[1]  R. Lefkowitz,et al.  β-arrestin- but not G protein-mediated signaling by the “decoy” receptor CXCR7 , 2009, Proceedings of the National Academy of Sciences.

[2]  G. Zaman,et al.  C5a-Stimulated Recruitment of β-Arrestin2 to the Nonsignaling 7-Transmembrane Decoy Receptor C5L2 , 2009, Journal of biomolecular screening.

[3]  K. Cianflone,et al.  C5a- and ASP-mediated C5L2 activation, endocytosis and recycling are lost in S323I-C5L2 mutation. , 2009, Molecular immunology.

[4]  P. Monk,et al.  The human complement fragment receptor, C5L2, is a recycling decoy receptor , 2009, Molecular immunology.

[5]  R. Alon,et al.  A crosstalk between intracellular CXCR7 and CXCR4 involved in rapid CXCL12‐triggered integrin activation but not in chemokine‐triggered motility of human T lymphocytes and CD34+ cells , 2008, Journal of leukocyte biology.

[6]  Arun K Shukla,et al.  Distinct conformational changes in β-arrestin report biased agonism at seven-transmembrane receptors , 2008, Proceedings of the National Academy of Sciences.

[7]  C. Mackay,et al.  Functional roles for C5a receptors in sepsis , 2008, Nature Medicine.

[8]  C. Mackay,et al.  Receptors for complement C5a. The importance of C5aR and the enigmatic role of C5L2 , 2008, Immunology and cell biology.

[9]  K. Cianflone,et al.  Acylation-stimulating protein/C5L2-neutralizing antibodies alter triglyceride metabolism in vitro and in vivo. , 2007, American journal of physiology. Endocrinology and metabolism.

[10]  P. Monk,et al.  Function, structure and therapeutic potential of complement C5a receptors , 2007, British journal of pharmacology.

[11]  Richard P. Harvey,et al.  Disrupted cardiac development but normal hematopoiesis in mice deficient in the second CXCL12/SDF-1 receptor, CXCR7 , 2007, Proceedings of the National Academy of Sciences.

[12]  K. Cianflone,et al.  Reduced adipose tissue triglyceride synthesis and increased muscle fatty acid oxidation in C5L2 knockout mice. , 2007, The Journal of endocrinology.

[13]  C. McKerlie,et al.  C5L2 is critical for the biological activities of the anaphylatoxins C5a and C3a , 2007, Nature.

[14]  P. Monk,et al.  Ligand Specificity of the Anaphylatoxin C5L2 Receptor and Its Regulation on Myeloid and Epithelial Cell Lines* , 2006, Journal of Biological Chemistry.

[15]  A. Rot,et al.  Throwing light on DARC. , 2006, Biochemical Society transactions.

[16]  G. Dohm,et al.  Lipid metabolism, exercise and insulin action. , 2006, Essays in biochemistry.

[17]  K. Cianflone,et al.  Effects of fatty acid regulation on visfatin gene expression in adipocytes. , 2006, Chinese medical journal.

[18]  L. Kuller,et al.  Anthropometry and Breast Cancer Risk in Nigerian Women , 2006, The breast journal.

[19]  M. Febbraio,et al.  AMP-activated protein kinase--the fat controller of the energy railroad. , 2006, Canadian journal of physiology and pharmacology.

[20]  G. Graham,et al.  Chemokine scavenging by D6: a movable feast? , 2006, Trends in immunology.

[21]  U. Smith,et al.  Increased levels of acylation-stimulating protein in interleukin-6-deficient (IL-6(-/-)) mice. , 2006, Endocrinology.

[22]  G. Bray,et al.  Obesity and Cardiovascular Disease: Pathophysiology, Evaluation, and Effect of Weight Loss , 2006, Arteriosclerosis, thrombosis, and vascular biology.

[23]  K. Cianflone,et al.  Targeting the signaling pathway of acylation stimulating protein Published, JLR Papers in Press, December 6, 2005. , 2006, Journal of Lipid Research.

[24]  Jacqueline Capeau,et al.  Recent advances in the relationship between obesity, inflammation, and insulin resistance. , 2006, European cytokine network.

[25]  J. Després,et al.  Is visceral obesity the cause of the metabolic syndrome? , 2006, Annals of medicine.

[26]  Pixu Liu,et al.  An Anti-inflammatory Function for the Complement Anaphylatoxin C5a-binding Protein, C5L2* , 2005, Journal of Biological Chemistry.

[27]  M. Oppermann,et al.  G Protein-coupled Receptor Kinases Promote Phosphorylation and β-Arrestin-mediated Internalization of CCR5 Homo- and Hetero-oligomers* , 2005, Journal of Biological Chemistry.

[28]  P. Monk,et al.  C5L2 Is a Functional Receptor for Acylation-stimulating Protein* , 2005, Journal of Biological Chemistry.

[29]  S. Tomlins,et al.  Evidence for a functional role of the second C5a receptor C5L2 , 2005, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[30]  X. Formiguera,et al.  Obesity: epidemiology and clinical aspects. , 2004, Best practice & research. Clinical gastroenterology.

[31]  R. Lefkowitz Historical review: a brief history and personal retrospective of seven-transmembrane receptors. , 2004, Trends in pharmacological sciences.

[32]  A. Tzafriri,et al.  Analysis of compartmental models of ligand-induced endocytosis. , 2004, Journal of theoretical biology.

[33]  M. Faraj,et al.  Differential regulation of fatty acid trapping in mouse adipose tissue and muscle by ASP. , 2004, American journal of physiology. Endocrinology and metabolism.

[34]  M. Steinmetz,et al.  Malonyl-CoA decarboxylase (MCD) is differentially regulated in subcellular compartments by 5'AMP-activated protein kinase (AMPK). Studies using H9c2 cells overexpressing MCD and AMPK by adenoviral gene transfer technique. , 2004, European journal of biochemistry.

[35]  R. Nibbs,et al.  The chemokine receptor D6 constitutively traffics to and from the cell surface to internalize and degrade chemokines. , 2004, Molecular biology of the cell.

[36]  K. Cianflone,et al.  ASP enhances in situ lipoprotein lipase activity by increasing fatty acid trapping in adipocytes Published, JLR Papers in Press, January 1, 2004. DOI 10.1194/jlr.M300299-JLR200 , 2004, Journal of Lipid Research.

[37]  K. Cianflone,et al.  Acylation-stimulating Protein (ASP)/Complement C3adesArg Deficiency Results in Increased Energy Expenditure in Mice* , 2004, Journal of Biological Chemistry.

[38]  V. Videm,et al.  Changes in Neutrophil Surface‐Receptor Expression After Stimulation with FMLP, Endotoxin, Interleukin‐8 and Activated Complement Compared to Degranulation , 2004, Scandinavian journal of immunology.

[39]  J. Després,et al.  Fasting acylation-stimulating protein is predictive of postprandial triglyceride clearance Published, JLR Papers in Press, October 16, 2003. DOI 10.1194/jlr.M300214-JLR200 , 2004, Journal of Lipid Research.

[40]  J. Krause,et al.  C5L2, a nonsignaling C5A binding protein. , 2003, Biochemistry.

[41]  K. Cianflone Acylation stimulating protein and triacylglycerol synthesis: potential drug targets? , 2003, Current pharmaceutical design.

[42]  P. Monk,et al.  The Chemoattractant Receptor-like Protein C5L2 Binds the C3a des-Arg77/Acylation-stimulating Protein* , 2003, The Journal of Biological Chemistry.

[43]  K. Cianflone,et al.  Critical review of acylation-stimulating protein physiology in humans and rodents. , 2003, Biochimica et biophysica acta.

[44]  Elaine C Meng,et al.  Constitutive Activation and Endocytosis of the Complement Factor 5a Receptor: Evidence for Multiple Activated Conformations of a G Protein‐Coupled Receptor , 2002, Traffic.

[45]  K. Cianflone,et al.  Acylation-stimulating Protein (ASP) Deficiency Induces Obesity Resistance and Increased Energy Expenditure in ob/obMice* , 2002, The Journal of Biological Chemistry.

[46]  John D Lambris,et al.  Increased C5a receptor expression in sepsis. , 2002, The Journal of clinical investigation.

[47]  P. Monk,et al.  The Orphan Receptor C5L2 Has High Affinity Binding Sites for Complement Fragments C5a and C5a des-Arg74 * , 2002, The Journal of Biological Chemistry.

[48]  Ralph Weissleder,et al.  Arthritis critically dependent on innate immune system players. , 2002, Immunity.

[49]  B. Jaber,et al.  C5a delays apoptosis of human neutrophils by a phosphatidylinositol 3-kinase-signaling pathway. , 2002, Kidney international.

[50]  H. Koistinen,et al.  Plasma Acylation Stimulating Protein Concentration and Subcutaneous Adipose Tissue C3 mRNA Expression in Nondiabetic and Type 2 Diabetic Men , 2001, Arteriosclerosis, thrombosis, and vascular biology.

[51]  N. Bunnett,et al.  The proliferative and antiapoptotic effects of substance P are facilitated by formation of a beta -arrestin-dependent scaffolding complex. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[52]  A. Beck‐Sickinger,et al.  Characterisation of G-protein-coupled receptors by antibodies. , 2000, Current medicinal chemistry.

[53]  D. Taub,et al.  Early Local Generation of C5a Initiates the Elicitation of Contact Sensitivity by Leading to Early T Cell Recruitment1 , 2000, The Journal of Immunology.

[54]  M. Enomoto,et al.  A putative chemoattractant receptor, C5L2, is expressed in granulocyte and immature dendritic cells, but not in mature dendritic cells. , 2000, Molecular immunology.

[55]  R. Lefkowitz,et al.  β-Arrestin1 Interacts with the Catalytic Domain of the Tyrosine Kinase c-SRC , 2000, The Journal of Biological Chemistry.

[56]  P. Havel,et al.  Acylation Stimulating Protein (ASP) Deficiency Alters Postprandial and Adipose Tissue Metabolism in Male Mice* , 1999, The Journal of Biological Chemistry.

[57]  K. Cianflone,et al.  Enhanced triglyceride clearance with intraperitoneal human acylation stimulating protein in C57BL/6 mice. , 1999, American journal of physiology. Endocrinology and metabolism.

[58]  Vu,et al.  Plasma acylation stimulating protein, adipsin and lipids in non‐obese and obese populations , 1999, European journal of clinical investigation.

[59]  S. Reynisdottir,et al.  Mechanisms Involved in the Regulation of Free Fatty Acid Release from Isolated Human Fat Cells by Acylation-stimulating Protein and Insulin* , 1999, The Journal of Biological Chemistry.

[60]  Y. Deshaies,et al.  Response of adipose tissue lipoprotein lipase to the cephalic phase of insulin secretion. , 1999, Diabetes.

[61]  K. Cianflone,et al.  Acylation stimulating protein (ASP), an adipocyte autocrine: new directions. , 1999, Seminars in cell & developmental biology.

[62]  M. Caron,et al.  Beta-arrestin-dependent formation of beta2 adrenergic receptor-Src protein kinase complexes. , 1999, Science.

[63]  M. Maslowska,et al.  Chylomicron-specific Enhancement of Acylation Stimulating Protein and Precursor Protein C3 Production in Differentiated Human Adipocytes* , 1998, The Journal of Biological Chemistry.

[64]  K. Cianflone,et al.  Coordinated release of acylation stimulating protein (ASP) and triacylglycerol clearance by human adipose tissue in vivo in the postprandial period. , 1998, Journal of lipid research.

[65]  U. Höpken,et al.  Impaired Inflammatory Responses in the Reverse Arthus Reaction Through Genetic Deletion of the C5a Receptor , 1997, The Journal of experimental medicine.

[66]  M. Delp,et al.  Physiological Parameter Values for Physiologically Based Pharmacokinetic Models , 1997, Toxicology and industrial health.

[67]  K. Cianflone,et al.  ASP stimulates glucose transport in cultured human adipocytes , 1997, International Journal of Obesity.

[68]  R. Zechner,et al.  The tissue-specific expression of lipoprotein lipase: implications for energy and lipoprotein metabolism. , 1997, Current opinion in lipidology.

[69]  K. Cianflone,et al.  Acylation-stimulating protein (ASP) regulates glucose transport in the rat L6 muscle cell line. , 1997, Biochimica et biophysica acta.

[70]  B. Spiegelman,et al.  Regulation of alternative pathway activation and C3a production by adipose cells. , 1996, Obesity research.

[71]  K. Cianflone,et al.  Differentiation‐induced production of ASP in human adipocytes , 1995, European journal of clinical investigation.

[72]  R. Gougeon,et al.  Response of plasma ASP to a prolonged fast. , 1995, International journal of obesity and related metabolic disorders : journal of the International Association for the Study of Obesity.

[73]  R. Eckel,et al.  Alterations in lipoprotein lipase in insulin resistance. , 1995, International journal of obesity and related metabolic disorders : journal of the International Association for the Study of Obesity.

[74]  G. Johnson,et al.  Mapping of the C5a receptor signal transduction network in human neutrophils. , 1994, Proceedings of the National Academy of Sciences of the United States of America.

[75]  L. Pitts,et al.  Fluid‐phase endocytosis of horseradish peroxidase by cerebral endothelial cells in primary culture: Characterization and kinetic analysis , 1994, Journal of neuroscience research.

[76]  K. Cianflone,et al.  Coordinate regulation of triacylglycerol synthesis and glucose transport by acylation-stimulating protein. , 1993, Metabolism: clinical and experimental.

[77]  T. Møller-Pedersen,et al.  Lipoprotein lipase activity in muscle tissue influenced by fatness, fat distribution and insulin in obese females , 1993, European journal of clinical investigation.

[78]  R. Eckel,et al.  Levels of acylation stimulating protein in obese women before and after moderate weight loss. , 1991, International journal of obesity.

[79]  K. Cianflone,et al.  The effect of ASP on the adipocyte of the morbidly obese. , 1989, The Journal of surgical research.

[80]  J. Gallin,et al.  Structural analysis of human neutrophil migration: Centriole, microtubule, and microfilament orientation and function during chemotaxis , 1977, The Journal of cell biology.

[81]  A. Klos,et al.  C5L2--an anti-inflammatory molecule or a receptor for acylation stimulating protein (C3a-desArg)? , 2007, Advances in experimental medicine and biology.

[82]  A. Russell Lipotoxicity: the obese and endurance-trained paradox , 2004, International Journal of Obesity.

[83]  C. Gerard,et al.  C5A anaphylatoxin and its seven transmembrane-segment receptor. , 1994, Annual review of immunology.

[84]  P. Nilsson-ehle,et al.  Impaired regulation of adipose tissue lipoprotein lipase in obesity. , 1981, International journal of obesity.

[85]  K. Cianflone,et al.  Printed in U.S.A. Copyright © 2000 by The Endocrine Society Reduced Body Weight, Adipose Tissue, and Leptin Levels Despite Increased Energy Intake in Female Mice Lacking Acylation-Stimulating Protein* , 2022 .